Recently, blockade of the immune checkpoints using monoclonal antibodies against cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-L1, has shown striking clinical results in cancer patients [9–13]. Here, CD274 is linked to cancer.